CYP2C19 and gastroesophageal reflux disease: (3) The University of Florida (Florida PGx) conducted multiple pragmatic, proof‐of‐concept trials,(Cavallari et al., 2017) two relevant for cross‐network analyses were: a comparative effectiveness study in patients with gastroesophageal reflux disease who were randomized to either conventional or CYP2C19‐guided proton pump inhibitor therapy with a primary outcome of GERD control; and a nonrandomized cluster study to compare the change in pain intensity with CYP2D6‐guided vs. usual chronic pain management in patients taking select opioids.